Intro

Sean McLean, founder of AvSci, shares insights on how his biotech company has grown to a public company with over $530 million in funding, utilizing AI to expedite biologic drug candidate discovery. The discussion explores the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025 and the intricacies of integrating AI into drug discovery while considering biological complexities.